Bendamustine

Common brands: Bendamustine, Rituxan, Cyclophosphamide, Frindovyx, Doxorubicin Hydrochloride

Top reporter: Meitheal Pharmaceuticals Inc.

CD20-directed Cytolytic Antibody [EPC]Corticosteroid [EPC]Alkylating Drug [EPC]Platinum-based Drug [EPC]Nucleoside Metabolic Inhibitor [EPC]
15,087
Total Reports
8,482
Serious Reports
3,265
Death Reports
30
Reported Reactions
Death Report Ratio: High (21.64%)

Patient Demographics

Male
7,239
Female
4,848

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Bendamustine.

# Reaction Reports % of Total
1 DISEASE PROGRESSION 2,198
11.4%
2 OFF LABEL USE 1,970
10.2%
3 NEUTROPENIA 1,141
5.9%
4 PYREXIA 1,039
5.4%
5 DRUG INEFFECTIVE 939
4.9%
6 THROMBOCYTOPENIA 934
4.8%
7 PNEUMONIA 827
4.3%
8 FEBRILE NEUTROPENIA 784
4.1%
9 ANAEMIA 756
3.9%
10 COVID-19 733
3.8%
11 DEATH 683
3.5%
12 INFECTION 560
2.9%
13 DIARRHOEA 502
2.6%
14 SEPSIS 463
2.4%
15 PANCYTOPENIA 444
2.3%
16 FATIGUE 425
2.2%
17 NAUSEA 412
2.1%
18 RASH 408
2.1%
19 DIFFUSE LARGE B-CELL LYMPHOMA 387
2.0%
20 MALIGNANT NEOPLASM PROGRESSION 379
2.0%
21 BLOOD LACTATE DEHYDROGENASE INCREASED 375
1.9%
22 DYSPNOEA 366
1.9%
23 PRODUCT USE IN UNAPPROVED INDICATION 347
1.8%
24 LYMPHOMA 346
1.8%
25 CYTOKINE RELEASE SYNDROME 338
1.8%
26 VOMITING 327
1.7%
27 PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY 318
1.6%
28 ACUTE KIDNEY INJURY 312
1.6%
29 PLASMA CELL MYELOMA 296
1.5%
30 CYTOMEGALOVIRUS INFECTION 288
1.5%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.